Infusion Biosciences Develops Breakthrough Testing Methods to Detect Cannabinoids in Water Solutions to Meet Food and Safety Standards

CANADA: Sproutly Canada has announced today that Infusion Biosciences have developed and verified analytical methods that detect, identify, and measure cannabinoid molecules in water-soluble (“Infuz2O”) and oil preparations (“Bio-Natural Oil”) derived from cannabis and hemp using APP Technology (collectively, the “Developed Analytics”). APP Technology is a patent pending process that uses proprietary reagents to recover naturally occurring water-soluble cannabinoids as well as the cannabis oils.

The proprietary methods for the Developed Analytics were created and refined during the past year through the work of Sproutly’s Chief Science Officer and Director Dr. Arup Sen in collaboration with state certified US testing laboratories. The delivery of the Developed Analytics satisfies Sproutly’s Earn Out Milestones (defined below) in the Acquisition Agreements (defined below) dated August 1, 2018 for the purchase of Infusion Biosciences Canada Inc. and SSM Partners Inc.

The cannabis industry has faced challenges in testing and measuring cannabinoid content in water formulations fortified with marijuana ingredients. Standard analytical methods used today for the detection and quantitation of cannabinoids had been designed for isolated oils and lack the ability to reliably measure cannabinoid contents in finished edible and beverage products. Correctly and reproducibly measuring the potency of bioactive cannabinoids in recreational, health and wellness, and medicinal beverage products is critical for successful marketing of these products in compliance with applicable food safety standards.

Dr. Arup Sen and Infusion have been successful in developing a proprietary method for processing Infuz2O preparations in order to detect tetrahydrocannabinol (“THC”), cannabidiol (“CBD”) and several other cannabinoids. The proprietary process allows for independent third-party testing laboratories to prepare the cannabis and hemp samples of Infuz2O so that analytical methods used by these laboratories can then detect and measure the natural water-soluble cannabinoids. The results obtained in collaboration with third-party laboratories utilized for this research verify the predicted levels of cannabinoids recovered by APP Technology in Infuz2O.

Furthermore, lab result comparisons of cannabinoid profiles of the cannabis biomass before and after each step of APP Technology have revealed no detectable change in composition of the major cannabinoids and no indication of selective separation of cannabinoids from biomass in either Infuz2O or Bio-Natural Oil. Additional chemical tests carried out during this research further confirmed the molecular identity of cannabinoids in Infuz2O and Bio-Natural Oils to be the same as standard cannabinoid molecules.

Sproutly intends to provide technical guidance to qualified third-party testing laboratories in order to enable them to analyze Infuz2O products to meet applicable regulatory authority requirements for commercial sale of Sproutly’s products.

“The ability to test for cannabinoids in water formulations has been unreliable for cannabis beverages globally due to the existing testing standards and practices,” said Dr. Arup Sen, Chief Science Officer and Director of Sproutly. “With ever increasing food-safety standards that need to be met for cannabis beverage and edible products, the completion of our research and the Developed Analytics are significant milestones in the commercialization of APP Technology; this is another step forward towards reliable and accurate testing for ingestible cannabis products.”

How ‘Gentleman Farmer’ Mike West Became The Cannabis Industry’s First Man Of Science

By Brandon A. Dorfman
@BADorfman

“I got into the [cannabis] industry because I was trying to grow plants to save my life,” Mike West told me over the phone recently. A farmer, researcher, and entrepreneur, West has an encyclopedic knowledge of cannabis that’s matched only by his passion for helping people.

“Nothing that the government’s going to do is going to prevent sick patients, sick parents from producing medicine for their children,” he continued.

I had asked West if legalization and the subsequent corporatization under the ‘Big Cannabis’ model had taken away from the art of growing, a constant lament of many of the old-school folks from the black market days. An accomplished academician that also considers himself a “gentleman farmer,” West was hesitant to see the issue in anything but shades of grey.

“We’re seeing a ton of technological innovations,” he told me. “Twenty years ago, there was traditional hash, that was about it. Over the last 10 years, we’ve come out with a couple different types of solvents — alcohol, butane, propane…” From there, he rattled off several significant steps forward taken over the past two decades, benefits that can only come from a legalized industry as opposed to a black market.

“Patient access ends up improving, [and] the cost in a lot of the recreational states has significantly decreased,” he said, ultimately making his point.

And West isn’t wrong. Aside from some high-priced craft flower, the benefits of legalization, and, in turn, corporatization, have been enormous. They include price drops as high as 80 percent in some states, making it extremely hard for groups like the cartels to stay in business.

The benefits to a scientist like West are immeasurable.

“[Access] improves, not only to more economical flower but a broader range of herbal supplements and nutraceuticals,” West told me. “And as a scientist, it opens up the door for doing that research that could potentially lead to future pharmaceuticals.”

Newlyweeds Pam Dyer and Mike West

But as much as the scientist in him loves to hear the machines purr, as he told me, the gentleman farmer understands that cannabis, legal or not, has always been about people. As legalization efforts in states like Washington opened the door for business, and really for scientific progress, patient’s rights began to fall to the wayside in many ways.

“I’ve been, pleasantly surprised the way that legalization has had and America being that laboratory of democracy,” West told me, adding in one caveat. “I love to talk about and constantly joke about … two steps forward one step back with when legalization happened.”

His main gripe, though perhaps that’s too stubborn a word to use, has to do with legislative bills that strip patients of their rights to homegrown medical cannabis. As the old-school black market crowd might say, it’s the death of the art of growing — only instead of science winning out; it’s for-profit patient care.

“As part of some of the bills, they took away some patients rights,” explained West, discussing corporate creep in the growing legalization movement. “Now there’s lots of home growers that are exporting illegally. And those are the ones that are getting clamped down on and having lots of people’s houses get raided.”

Despite his years of entrepreneurship — or, perhaps, guided by them — West has always been a patient advocate first. And I could hear that in his voice as we spoke. Even in states where home grows are allowed, patients still run the risk of being harassed by law enforcement, a terrible situation for all involved.

As for my original question, though, had forward progress spelled death for the so-called art of growing cannabis?

Mike West is positive if he’s nothing else.

“It’s something,” he told me, “you got to take the good with the bad.”

“I love the science side of it…”

West first took an interest in cannabis sometime in the late 1990s. With an epileptic sister and other family members suffering from various ailments and illnesses he became what he referred to as a ‘cannabis refugee,’ traveling from Texas to Colorado — in his case not just looking for the plant, but looking to study the plant.

“I ended up seeing a research study looking at treating epilepsy with cannabis,” he told me, speaking of his earnest beginnings that would go on to launch a now 20-plus year career. “[I] tried to go to school to study cannabis, but they didn’t allow us to study cannabis at the time. So we ended up studying kind of a mix of molecular biochemistry and international law, and I ended up focusing on trying to research biofuels.”

Unfortunately, when it comes to studying cannabis, not much has changed today. At one point in our conversation, West mentioned a few universities are now teaching horticultural classes or showing students how to run analytical testing equipment for use in the cannabis industry. Due to federal law, none of them can offer hands-on experience with the plant.

For West, however, the hands-on experience came easy. Whether he was working at dispensaries or hydro shops in college, or even, as he told me, doing a small stint at a law firm helping medical growers become medical collectives, West was always learning.

Mike West Positive Nelson

“My passion — I more than anything consider myself a research scientist,” West said. “Obviously [I] can’t do that research science at universities, currently very few allow any cannabis research. The federal government makes university research hard.”

“I focused on trying to do as much research as I can in the private sector,” he said, reminding me of the path that most people with a science-focus have to take in this industry.

To-date, according to West, he’s built medical labs in around 13 or 14 states, hemp labs in six states, and recreational cannabis labs in four states. He’s currently working with a Canadian company that’s building labs in Kansas, outside of Vancouver, and outside of Toronto — not to mention the fact that they also have some operations going on over in Australia and Europe. Then there are the hemp labs in Oregon, Colorado, and Washington, and the teams he’s training in Kentucky too.

“I love the science side of it,” he told me in the most laid back voice possible.

Since those early days in Colorado as a ‘cannabis refugee,’ Mike West has established himself as one of the preeminent researchers in the cannabis industry. As a researcher, entrepreneur, author, and adviser to numerous companies in the medical, adult use cannabis, hemp farming, extraction, and products industries his bio reads like a crossbreed somewhere between Raphael Mechoulam and Jack Herer.

But he’s never lost his initial drive nor forgotten what turned him to cannabis in the first place.

“Having family members that were medical patients really got me interested in developing products,” West said as we continued our conversation. “Unfortunately, it’s incredibly difficult to do that research under the same methodology that’s done with traditional pharmaceutical research.”

When he’s not helping to set up the next great laboratory or medical collective or hemp farm, Mike West is focusing on phytocannabinoids and working with patient-driven studies. Again though, the inability to do research at university labs makes the process difficult for West and the industry at-large.

So, he told me they use workarounds. A lot of that involves bringing university professors, doctors, naturopaths, or herbalist to him. For example, he told me, he’ll hold educational seminars, and bring these specialists into the dispensaries, saying to the patients hey if you have this medical condition these are the products that may or may not work better for you.

It’s a way to collect user surveys; to collect data.

“Being able to collect user surveys, you can start to make those correlations,” he said.

Beyond the issue of university research, West and I discussed the difficulty he and others like him have when it comes to finding an adequate product to use in testing. For those in the academy fortunate enough to work with cannabis, the quality is — well, it’s schwag.

“If you want to do research at the university, you have to get approved by the FDA, by the DEA by NIDA — the National Institute on Drug Abuse,” said West, explaining the harrowingly frustrating process. “NIDA contracts out their cultivation to currently one producer, [the] University of Mississippi and University Mississippi doesn’t have passionate cultivators.”

West told me how his team wanted to use the government schwag for a PTSD trial in Colorado. They obviously wanted to test the product to make sure that they were not providing anything dangerous to the patients first.

Under Colorado’s regulated market, the federal government’s cannabis didn’t pass the test for microbial contaminants.

“We’re seeing this weird juxtaposition where the black market or legal market or medical market is able to produce a higher quality product than the U.S. Government,” West lamented. “[It’s] nothing more than ignorance, in my opinion.”

He continued: “A lot of the universities are forced to take a hurry up and wait approach because they’re forced to wait for the federal government to hurry up and change the laws.”

“…teach them as much as we can.”

A few days or weeks before our conversation, Mike West was sitting in a classroom learning his trade. After 20-plus years in the industry, the one thing he’s learned is that he has much more to learn.

“That’s the real key to success in this industry is learning how to be as efficient as possible and as responsible as possible,” he told me towards the end of our conversation. “And if you can throw in a dash of big corporate social responsibility, ultimately, I think that a lot there’s a ton of opportunities in the cannabis industry for entrepreneurs.”

Which brought us to CANNAVAL, the first educational medical cannabis and hemp conference and expo in the U.S. Virgin Islands. The event, which will be hosted by former senator and now Agriculture Commissioner Positive T.A. Nelson, along with 420MEDIA in association with NT Media Productions looks to be one of the key gatherings of industry professionals this summer. And Mike West is scheduled to speak.

“We organized a tour of a couple of farms and retail shops and processing labs and testing labs so they can the see the steps in the political process that it goes from the time you plant the seed to the time that it goes to the retailer,” West told me, explaining how he first met then-Sen. Nelson. Without the agricultural commissioner, the Virgin Islands may very well not have medical cannabis today. The effort he put in towards helping that law pass was crucial.

“Nelson spent the last couple of years getting that law passed,” said West. “That opens up the Virgin Islands to start allowing the farmers to get licenses to do what they’ve been doing for decades.”

“We want to be able to make sure that the farmers start off on a good foot,” he continued.

Unlike other cannabis events, CANNAVAL is designed to educate and empower. It will give all those who attend, including companies and organizations an exclusive opportunity to network with government officials, entrepreneurs, medical and seasoned professionals in an open and welcoming environment that will cultivate and inspire.

And the guest list is top notch as well, including some of the cannabis industry’s biggest names such as Sierra Riddle. Dan Herer, Adam Dunn, Roz McCarthy, and, of course, Agricultural Commissioner Positive Nelson.

And Mike West.

“I think there’s a dance Friday, Saturday’s the conference, and then Sunday — what’s going to beat a networking day hanging out on the beach and enjoy some of that beautiful Caribbean sun,” West said, clearly excited to be a part of the event.

But for West, he’s going to do what he always does.

“We’re looking at trying to set up a conference,” said West, echoing what Positive Nelson told him. “To educate the consumers, educate potential business people in the Virgin Islands, teach them as much as we can.”

Sproutly Canada CEO Keith Dolo On Water-based Cannabinoid Technologies

CANADA:   Sproutly Canada Inc (CNSX:SPR) CEO Keith Dolo outlines how Sproutly’s development of water-based cannabinoid technologies, allowing the body to absorb THC and CBD compounds through water-solubility, rather than traditional oil based absorption.

The benefit of water-soluble cannabinoids is the quickened onset and offset times of cannabinoid ingestion while providing a higher level of control pertaining to dosage and duration. Sproutly looks forward to marketing their edible and beverage products to the public in Canada next year as consumables become legal in Canada.

For more information, log on to www.sproutly.ca.
[youtube http://www.youtube.com/watch?v=nbNEhwYJMXc&w=560&h=315]

Nanoparticle Drones To Target Lung Cancer with Radiosensitizers And Cannabinoids

imageWilfred Ngwa1,2*, imageRajiv Kumar1,3imageMichele Moreau1,2imageRaymond Dabney4 and imageAllen Herman4

1Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
2University of Massachusetts Lowell, Lowell, MA, United States
3Northeastern University, Boston, MA, United States
4Cannabis Science Inc., Irvine, CA, United States
 
CALIFORNIA: Nanotechnology has opened up a new, previously unimaginable world in cancer diagnosis and therapy, leading to the emergence of cancer nanomedicine and nanoparticle-aided radiotherapy. Smart nanomaterials (nanoparticle drones) can now be constructed with capability to precisely target cancer cells and be remotely activated with radiation to emit micrometer-range missile-like electrons to destroy the tumor cells. These nanoparticle drones can also be programmed to deliver therapeutic payloads to tumor sites to achieve optimal therapeutic efficacy. In this article, we examine the state-of-the-art and potential of nanoparticle drones in targeting lung cancer. Inhalation (INH) (air) versus traditional intravenous (“sea”) routes of navigating physiological barriers using such drones is assessed. Results and analysis suggest that INH route may offer more promise for targeting tumor cells with radiosensitizers and cannabinoids from the perspective of maximizing damage to lung tumors cells while minimizing any collateral damage or side effects.

Introduction

Nanomedicine, the application of nanotechnology to medicine, has opened a new, previously unimaginable world in cancer diagnosis and therapy. Today new multifunctional nanoplatforms or smart nanomaterials (nanoparticle drones) can be constructed and endowed with image contrast enhancement capabilities for techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) (12) and can contain therapeutic payloads programmed for targeted delivery to disease sites (3). The vision of combining diagnostics and therapeutics, now being referred to as theranostics, was considered futuristic only a few years ago but is now clearly achievable—the future is almost now!

A) Cartoon showing both intravenous and inhalation (INH) delivery of nanoparticle drones; (B) TEM image of lung tumor targeted with drones; (C) absorption spectra of drone technology uniquely customized for INH delivery to lung tumors.

A) Cartoon showing both intravenous and inhalation (INH) delivery of nanoparticle drones; (B) TEM image of lung tumor targeted with drones; (C) absorption spectra of drone technology uniquely customized for INH delivery to lung tumors.

Recognizing the potential impact of nanomedicine, the National Cancer Institute created the Alliance for Cancer Nanotechnology to leverage the potential of nanotechnology toward transforming the way cancer is diagnosed, treated, or prevented. Projects funded by this Alliance have led to significant research breakthroughs and have even entered successful clinical trials (4). Today, cancer nanomedicine now includes burgeoning research and development in nanoparticle-aided radiotherapy (NRT). A recent article (5) provides a robust review of NRT developments for over a decade in NRT with gold nanoparticles (GNPs), highlighting emerging approaches, challenges, and opportunities for further research toward clinical translation. Beyond GNP, other research has highlighted the use of alternative nanoparticle platforms like gadolinium nanoparticles (67), hafnium nanoparticles (8), platinum-based chemotherapy drug platforms, and others with theranostic capability (910).

In general, the key goal for NRT and cancer drug development efforts is the same, which is to optimize therapeutic efficacy/ratio. To this end, recent advances in the design of smart nanomaterials proffer tremendous potential toward realizing this goal. Such smart materials (11) are specifically designed to be sensitive to a specific stimulus, such as temperature, magnetic field, ultrasound intensity, light or radiation, and pH, and to then respond in active ways including radiosensitization or changing their structure for drug delivery, or other functions that have the potential to cogently enhance treatment outcomes.

Gold nanoparticles provide an excellent template for building such nanoparticle drones. They are biocompatible radiosensitizers (5), proffering relatively no toxicity. They can readily interact with photons by the photoelectric effect, to emit missile-like photoelectrons or Auger electrons in the micrometer range, to substantially boost RT damage to cancer cells. In the photoelectric effect, photons interact with the nanomaterials, with the probability of photoelectric interaction inversely proportional to the cube of the photon energy (5). Once the photoelectron is emitted, this creates a vacancy that may be filled by an electron from a higher energy level. The resulting release of energy could then also knockout Auger electrons. The Auger electrons are shorter range and with high linear energy transfer, so can lead to highly localized damage. Such highly localized damage to tumor cells can allow minimization of the primary radiotherapy dose and hence normal tissue toxicity. Nanoplatforms such as GNPs are also particularly attractive for building nanoparticle drones because they can provide CT and photoacoustic imaging contrast and are suitable for drug loading and attaching targeting moieties. Depending on surface functionalization, type of drug, and desired application, GNPs can be easily loaded with drugs or other molecules through either non-covalent interactions or covalent conjugation. Loading of drugs onto GNPs may improve their stability and biodistribution in biological media since the drugs are protected in the carrier. In short, multifunctional nanoparticle drones based on GNPs hold great promise in cancer nanomedicine.

 

Pot Research Stalled Even As Legalization Gains Momentum

DISTRICT OF COLUMBIA: Speaking by phone, Anthony Fabrizio was on a roll about his career in cannabis research when he suddenly fell silent. You could hear the San Francisco–based research director stammering, then grunting. Silence again.

Fabrizio returned to the conversation more than 10 seconds later. He chose his next words gingerly, like someone trying to find a light switch in a dark room, placing one hand in front of the other.

“I … just had a seizure,” he said. The research director for Terra Tech Corp., a public company based in Irvine, California, suffers absence seizures (sometimes called petit mal seizures) due to epilepsy. He credits smoking marijuana with reducing the number of seizures from about 20 a week to one every few months. Fabrizio, 27, a biochemist, has since become an evangelist for medical marijuana, which is legally available in 23 states and the nation’s capital, with legislation underway in other states.

Despite the growing momentum for pot legalization, marijuana remains one of the most difficult substances to study in the United States.